Details

Autor(en) / Beteiligte

• Olson, Samantha M
• Newhams, Margaret M
• Halasa, Natasha B
• Price, Ashley M
• Boom, Julie A
• Sahni, Leila C
• Irby, Katherine
• Walker, Tracie C
• Schwartz, Stephanie P
• Pannaraj, Pia S
• Maddux, Aline B
• Bradford, Tamara T
• Nofziger, Ryan A
• Boutselis, Benjamin J
• Cullimore, Melissa L
• Mack, Elizabeth H
• Schuster, Jennifer E
• Gertz, Shira J
• Cvijanovich, Natalie Z
• Kong, Michele
• Cameron, Melissa A
• Staat, Mary A
• Levy, Emily R
• Chatani, Brandon M
• Chiotos, Kathleen
• Zambrano, Laura D
• Campbell, Angela P
• Patel, Manish M
• Randolph, Adrienne G

Titel

Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12-18 Years - United States, June-September 2021

Ist Teil von

• MMWR. Morbidity and mortality weekly report, 2021-10, Vol.70 (42), p.1483-1488

Ort / Verlag

United States: U.S. Government Printing Office

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• Pfizer-BioNTech COVID-19 vaccine is authorized for use in children and adolescents aged 12-15 years and is licensed by the Food and Drug Administration (FDA) for persons aged ≥16 (1). A randomized placebo-controlled trial demonstrated an efficacy of 100% (95% confidence interval [CI] = 75.3%-100%) in preventing outpatient COVID-19 in persons aged 12-15 years (2); however, data among adolescents on vaccine effectiveness (VE) against COVID-19 in real-world settings are limited, especially among hospitalized patients. In early September 2021, U.S. pediatric COVID-19 hospitalizations reached the highest level during the pandemic (3,4). In a test-negative, case-control study at 19 pediatric hospitals in 16 states during June 1-September 30, 2021, the effectiveness of 2 doses of Pfizer-BioNTech vaccine against COVID-19 hospitalization was assessed among children and adolescents aged 12-18 years. Among 464 hospitalized persons aged 12-18 years (179 case-patients and 285 controls), the median age was 15 years, 72% had at least one underlying condition, including obesity, and 68% attended in-person school. Effectiveness of 2 doses of Pfizer-BioNTech vaccine against COVID-19 hospitalization was 93% (95% CI = 83%-97%), during the period when B.1.617.2 (Delta) was the predominant variant. This evaluation demonstrated that 2 doses of Pfizer-BioNTech vaccine are highly effective at preventing COVID-19 hospitalization among persons aged 12-18 years and reinforces the importance of vaccination to protect U.S. youths against severe COVID-19.